Hypertriglyceridemia Associated with Use of Sunitinib to Treat a Metastatic Pancreatic Neuroendocrine Tumor.
10.3904/kjm.2015.88.1.101
- Author:
Sanghoon YOO
1
;
Insook WOO
;
Yun Hwa JUNG
;
Gyohui KIM
;
Youngyun CHO
;
Chi Wha HAN
Author Information
1. Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea. cwhan@unitel.co.kr
- Publication Type:Case Report
- Keywords:
Sunitinib;
Hypertriglyceridemia;
Neuroendocrine tumor;
Hypothyroidism
- MeSH:
Carcinoma, Renal Cell;
Cardiac Output;
Diarrhea;
Esophagitis;
Fatigue;
Female;
Gastrointestinal Stromal Tumors;
Heart Ventricles;
Humans;
Hyperglycemia;
Hypertension;
Hypertriglyceridemia*;
Hypothyroidism;
Lipid Metabolism;
Nausea;
Neuroendocrine Tumors*;
Pancreas;
Pancreatectomy;
Protein-Tyrosine Kinases;
Skin;
Stomatitis
- From:Korean Journal of Medicine
2015;88(1):101-105
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Sunitinib is a multi-target tyrosine kinase inhibitor used to treat gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. The most common adverse reactions are known to be nausea, fatigue, diarrhea, stomatitis, esophagitis, hypertension, skin toxicity (hand-foot syndrome), hypothyroidism, and reduction in the cardiac output of the left ventricle. Herein, we report the case of a 57 year-old female who visited our hospital complaining of epigastric pain. She had been taking sunitinib at 25 mg/day to treat a metastatic pancreatic neuroendocrine tumor. Upon computed tomography performed on admission, we observed that fluid had collected around the pancreas. Laboratory analysis revealed hypertriglyceridemia (triglycerides 993 mg/dL). Tyrosine kinase inhibitors are known to have limited effects on lipid metabolism. In this case, we suggest that hyperglycemia seems to have had a limited effect on lipid levels. We are rather of the view that hyperglycemia, a history of distal pancreatectomy, and hypothyrodisim, indirectly caused the observed hypertriglyceridemia.
